DiaSorin Molecular announced that it has released a new primer pair for use in laboratory-developed molecular tests that targets the yeast Candida auris. The company is a provider in the development and manufacture of primer pairs with a menu of more than 65 products for bacterial, viral and fungal targets, as well as human genetic mutations. The primer pairs are classified as Analyte Specific Reagents (ASRs), which can be used by high-complexity laboratories to develop their own laboratory developed tests (LDTs).
C. auris, according to the CDC, is a quickly emerging drug-resistant yeast that spreads in healthcare facilities and is a serious global health threat. It is often difficult to identify with non-molecular methods, with misidentification leading to poor and costly patient management. The yeast is often multi-drug resistant and has caused recent outbreaks in hospitals and long-term care facilities across the U.S and in more than 20 countries. Since the organism is becoming more common, effective and timely identification of the organism is required for mitigation of this threat.